Henry M. Jackson Foundation for the Advancement of Military Medicine

Texas A&M Health, Wave Neuroscience Announce Second Phase of PTSD Clinical Trial

Retrieved on: 
Thursday, December 2, 2021
Health, Clinical Trials, Mental Health, Medical Devices, Linda, Patient, Substance abuse, Safety, Uniformed Services University of the Health Sciences, Disease, Physics, Brain, Outline of health sciences, Data collection, Post-traumatic stress disorder, PPCS, PTSD, MD, Bryan–College Station, Post-concussion syndrome, Precision medicine, Clinical trial, Texas A&M Health Science Center College of Medicine, Doctor of Philosophy, Nursing, History, Henry M. Jackson Foundation for the Advancement of Military Medicine, Technology, Twitter, Texas Tech University Health Sciences Center, List of life sciences, United States Special Operations Command, Biotechnology, Depression, Public health, Traumatic brain injury, TBI, Medicine, Pharmacy, Dentistry, Wave, Magnetism, Quality of life, Pharmaceutical industry, Medical imaging

Texas A&M University Health Science Center (Texas A&M Health) and Wave Neuroscience announced the second phase of their post-traumatic stress disorder (PTSD) clinical trial today.

Key Points: 
  • Texas A&M University Health Science Center (Texas A&M Health) and Wave Neuroscience announced the second phase of their post-traumatic stress disorder (PTSD) clinical trial today.
  • The clinical trial is being directed by Kenneth Ramos, MD, PhD, executive director of Texas A&M Health Institute of Biosciences and Technology.
  • Likewise, Wave Neuroscience, an innovative company focused on brain health, is a pioneer in offering treatments that have shown promise in optimizing brain performance.
  • Were tremendously honored to be collaborating with Texas A&M Health and Dr. Ramos, said Dr. Erik Won, MD, President and Chief Medical Officer at Wave Neuroscience.

Henry M. Jackson Foundation Expands Eye-Tracking Partnership with Neurolign Technologies to Advance Neurological Military Medicine

Retrieved on: 
Tuesday, November 23, 2021
CEO, Henry M. Jackson Foundation for the Advancement of Military Medicine, Technology, Kinetics, Eye, Partnership, PTSD, Health, Neuro, Concussion, Veteran, Neurodegeneration, Research, Organization, Military medicine, FDA, Traumatic brain injury, War, Medical imaging, Pharmaceutical industry

TORONTO, Nov. 23, 2021 /PRNewswire/ -- Neurolign Technologies , the global leader in clinical eye-tracking and neuro-functional diagnostic testing, today announced the expansion of an ongoing strategic partnership with the Henry M. Jackson Foundation for the Advancement of Military Medicine.

Key Points: 
  • TORONTO, Nov. 23, 2021 /PRNewswire/ -- Neurolign Technologies , the global leader in clinical eye-tracking and neuro-functional diagnostic testing, today announced the expansion of an ongoing strategic partnership with the Henry M. Jackson Foundation for the Advancement of Military Medicine.
  • "We're incredibly proud of Neurolign's successful involvement within the military and veteran health sector," said Eugene Melnyk, CEO, Chairman, and founder of Neurolign.
  • By augmenting their collaboration with Neurolign, through additional tech and research resources, the foundation will continue their robust research efforts into understanding the neurological health implications of combat.
  • Soon after their founding, Neurolign acquired Neuro Kinetics Inc., a long-time industry player, incorporating their technology into Neurolign solutions.

Life-Saving Donation Made by Military Medical Research Nonprofit to Local Police Departments

Retrieved on: 
Monday, September 20, 2021
Invention, Trauma, Man, Henry M. Jackson Foundation for the Advancement of Military Medicine, Austin Police Department, Bandage, Texas Department of State Health Services, Multimedia, Tourniquet, Bleeding, American Rescue Plan Act of 2021, Hospital, Heart, NAR, CEO, Medicine, Life, Woman, SAN, Military medicine, HJF, Pharmaceutical industry

HJF donates hundreds of military medical first aid kits to San Antonio and Austin Police Departments.

Key Points: 
  • HJF donates hundreds of military medical first aid kits to San Antonio and Austin Police Departments.
  • While tourniquets and bandages have been used to treat trauma for hundreds of years, military medical research projects have resulted in meaningful upgrades to these devices.
  • Known as Military City, USA, San Antonio is a nexus of military medicine with more than a dozen military health system units and hundreds of research programs in progress throughout the area.
  • "It's gratifying for HJF to donate kits exemplifying the contributions military medicine has made for all to the San Antonio and Austin police departments."

Treatment for Critically Ill COVID Patients Begins 1st Randomized Clinical Trial

Retrieved on: 
Tuesday, August 31, 2021
Research, Medical Devices, Medical Supplies, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Jean-Louis Vincent, Sepsis, COVID, Blood, Enrollment, Virus, Physician, Communication, Survival, Infection, Observational study, Bacteria, Fungus, Pandemic, Person, Research, Food, Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation for the Advancement of Military Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Outline of health sciences, EUA, Septic shock, Hospital, ICU, USU, Mortality, Safety, Heparin, Survival rate, News, Patient, Septic, Dow University of Health Sciences, IDE, DARPA, FDA, COVID-19, Military medicine, Pharmaceutical industry, Risk management, ExThera Medical Corporation, Seraph 100, EXTHERA MEDICAL CORPORATION, SERAPH 100

The first multicenter randomized controlled trial of the Seraph 100, which has successfully treated hundreds of COVID patients, will be studying the treatments ability to reduce ICU length of stay, hospital duration and mortality in patients suffering from septic shock..

Key Points: 
  • The first multicenter randomized controlled trial of the Seraph 100, which has successfully treated hundreds of COVID patients, will be studying the treatments ability to reduce ICU length of stay, hospital duration and mortality in patients suffering from septic shock..
  • The initial findings in our observational study for COVID patients have been very promising.
  • The study will evaluate the safety and efficacy of pathogen-removing extracorporeal blood purification therapy in critically ill patients with pathogen-associated shock utilizing ExTheras Seraph 100 filter.
  • ExThera Medicals extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections.

HJF Collaborates with Google Health and DoD to Use AI to Understand and Treat Breast Cancer Tumors

Retrieved on: 
Wednesday, August 11, 2021
Breast cancer, Factor X, Henry M. Jackson Foundation for the Advancement of Military Medicine, Histology, Military medicine, Artificial intelligence, HJF, Program, Cancer, Research, Deep learning, Multimedia, Neoplasm, OU School of Community Medicine, Biomarker, Naval Medical Center San Diego, Google Health, AI, HER2, Medical imaging

AI can predict three important biomarkers found in breast cancer.

Key Points: 
  • AI can predict three important biomarkers found in breast cancer.
  • Treatment plans forbreast cancer, one of the most common forms of cancer in the United States, rely on identification of biological molecules within the body, called biomarkers.
  • This research is the product of an ongoing collaboration between Google Health, NMCSD, and HJF.
  • This paper builds on research done in 2017 and 2018 where AI models were trained to identify metastatic breast cancer.

HJF Co-Hosts COVID-19 Research Day for DoD Partners

Retrieved on: 
Wednesday, June 30, 2021
Henry M. Jackson Foundation for the Advancement of Military Medicine, Walter Reed Army Institute of Research, Healthcare in the United States, Health care, United States

HJF co-hosts a day of virtual COVID-19 medical research presentations with DoD partners.

Key Points: 
  • HJF co-hosts a day of virtual COVID-19 medical research presentations with DoD partners.
  • "Since 1983, HJF has supported the critical work being done by our DoD partners to make our Nation's warfighters more agile, resilient, and survivable.
  • "The breadth of research presented at the COVID-19 Research Day was astounding, and we are gratified to have convened this event with co-hosts USU and WRAIR," said Dr. Caravalho.
  • "HJF is proud to stand alongside all our DoD partners, encouraging collaboration and supporting the ongoing fight against COVID-19."

HJF Receives Patent for Potential Treatment for Nerve Agent Exposure

Retrieved on: 
Tuesday, May 11, 2021
Drugs, Acetylcholinesterase inhibitors, Psychoactive drugs, Medicine, Antidotes, Nerve agent, Atropine, Organophosphate, Anticholinergic, Henry M. Jackson Foundation for the Advancement of Military Medicine, Autoinjector

b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.

Key Points: 
  • b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.
  • The therapy was shown to be effective even with delayed use following nerve agent exposure.
  • Currently, treatment for OP exposure is with an anticholinergic agent administered immediately after exposure; thus, military personnel may receive kits containing atropine auto-injectors for use in the event of a nerve-gas attack.\nDr.
  • Importantly, this new combination therapy also extends the therapeutic window, as it is effective even when administered hours after OP exposure.

Honoring the Heroes of Military Medicine

Retrieved on: 
Tuesday, May 4, 2021
Henry M. Jackson Foundation for the Advancement of Military Medicine, Medical research, COVID-19 vaccine, Medicine, Health sciences, Health care

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) honors individuals and organizations involved in this response at its annual Heroes of Military Medicine awards ceremony.

Key Points: 
  • The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) honors individuals and organizations involved in this response at its annual Heroes of Military Medicine awards ceremony.
  • With the support of the Chairman Sponsor, Health Net Federal Services ,HJF recognizes individuals and organizations who have made outstanding contributions in advancing medicine for our nation's warfighters, veterans and civilians.\nHJF is honoring those involved in the fight against COVID-19 with the 2021 Heroes of Military Medicine.\nThis year, 20thChairman of the Joint Chiefs of Staff, General Mark A. Milleywill deliver the keynote address honoring the work of those combating COVID-19.\nBecause of the pandemic, last year's Heroes of Military Medicine event was cancelled.
  • Only awardees and program participants will attend in person, and the event will be live-streamed for all other guests.\nThe 2021 Heroes of Military Medicine Award Honorees are:\nThe Hero of Military Medicine Ambassador Award is presented to the multiple companies that accomplished the herculean feat of creating, manufacturing, and distributing a COVID-19 vaccine in less than a year.\nThe Hero of Military Medicine Senior Leader Award is presented to General Gustave F. Perna of the U.S. Army .
  • In this position, he co-leads the partnership to accelerate the development, manufacturing and distribution of COVID-19 vaccines and therapeutics.\nThe Heroes of Military Medicine Honorees are:\n"

PhysIQ, Department of Defense, Duke University, Johns Hopkins and HJF Partner to Study COVID-19

Retrieved on: 
Tuesday, May 4, 2021
Other Health, Pharmaceutical, Oncology, Medical devices, Infectious diseases, Hospitals, University, Education, Clinical trials, Cardiology, Biotechnology, Nursing, Health, Henry M. Jackson Foundation for the Advancement of Military Medicine, Johns Hopkins University, Biosensor, Johns Hopkins, Education, United States, MARYLAND, HJF, physIQ, HJF, PHYSIQ

These signals will also support the evaluation of novel products for treatment and prevention of COVID-19.\nThis press release features multimedia.

Key Points: 
  • These signals will also support the evaluation of novel products for treatment and prevention of COVID-19.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210504005187/en/\nPhysIQ, Department of Defense, Duke University, Johns Hopkins and HJF Partner to Study COVID-19 (Graphic: Business Wire)\nPhysIQ, a company that specializes in collecting and analyzing continuous physiological data acquired from wearable biosensors, will deploy its pinpointIQTM platform at Johns Hopkins University and Duke University in support of the study.
  • For more than 35 years, HJF has partnered with researchers and clinicians to provide bench to beside to battlefield research support.
  • More than 3,000 HJF teammates ensure HJF is a trusted and responsive partner by providing scientific, administrative and program operations services to researchers in the military, academia, and private industry.

HJF has more than 200 technologies available for license

Retrieved on: 
Tuesday, March 23, 2021
Henry M. Jackson Foundation for the Advancement of Military Medicine, Intellectual property law, Technology transfer, License, Articles

The showcase is highlighting a selection of the more than 230 technologies HJF has available for license.

Key Points: 
  • The showcase is highlighting a selection of the more than 230 technologies HJF has available for license.
  • HJF is the trusted partner of choice in technology transfer for innovations generated through HJF's multiple research partnerships throughout the DoD and Federal Government.
  • HJF is showcase a selection of the more than 230 medical technologies HJF has available for license.
  • These research projects have resulted in hundreds of patents, with licensed technologies generating over $1B in product sales.